The Role of JAK2 in Myeloproliferative Diseases Diagnosis
Downloads
Janus Kinase 2 (JAK2) plays an important role in mediating transduction signal of hematopoiesis, including in the pathogenesis of Myeloproliferative diseases (MPD). Various studies have been carried out to identify the position of aleles in tyrosine encoding mutations. Although the effect of JAK2 mutations is still not fully understood, the discovery of these mutations might be able to differentiate the types of polycythaemia vera, essential thrombocytemia, and primary myelofibrosis with malignant abnormalities. WHO has revised the MPD diagnosis criteria following this finding. This review will discuss the role of JAK2.
Kiladjian JJ. The Spectrum of JAK2-Positive Myeloproliferative Neoplasms. Hematology American Society of Hematology Education Program. 2012; 2012: 561-6.
Spivak JL and Silver RT. The Revised World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocytosis, and Primary Myelofibrosis: an Alternative Proposal. Blood. 2008; 112: 231-9.
Latif N, Guthrie T and Rana F. JAK2 Gene Mutation: Impact on Pathogenesis, Classification, and Management of Myeloproliferative Neoplasms. 2010, p.109–14.
Tefferi A. JAK2 Mutations and Clinical Practice in Myeloproliferative Neoplasm. Cancer Journal. 2007; 13: 366–71.
Sansone P and Bromberg J. Targeting the Interleukin-6/JAK/STAT Pathway in Human Malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012; 30: 1005-14.
Haan C, Kreis S, Margue C and Behrmann I. JAKs And Cytokine Receptors--An Intimate Relationship. Biochem Pharmacol. 2006; 72: 1538-46.
O'Shea JJ. JAKs, STATs, Cytokine Signal Transduction, and Immunoregulation: Are We There Yet? Immunity. 1997; 7: 1-11.
McLornan D, Percy M and McMullin MF. JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders. The Ulster medical journal. 2006; 75: 112-9.
Seavey MM and Dobrzanski P. The Many Faces of Janus Kinase. Biochem Pharmacol. 2012; 83: 1136-45.
Bromberg J. STAT Proteins and Oncogenesis. The Journal of clinical investigation. 2002; 109: 1139-42.
Tefferi A and Vainchenker W. Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011; 29: 573-82.
Hou SX, Zheng Z, Chen X and Perrimon N. The JAK/STAT Pathway in Model Organisms: Emerging Roles in Cell Movement. Developmental cell. 2002; 3: 765-78.
Agarwal MB. Clinical Applications of Molecular Haematology: JAK2 in Myeloproliferative Disorders. The Journal of the Association of Physicians of India. 2007; 55: 507-10.
Hsu HC. Pathogenetic Role of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. Journal of the Chinese Medical Association : JCMA. 2007; 70: 89-93.
James C, Ugo V, Le Couedic JP, et al. A Unique Clonal JAK2 Mutation Leading to Constitutive Signalling Causes Polycythaemia Vera. Nature. 2005; 434: 1144-8.
Tefferi A, Lasho TL, Schwager SM, et al. The Clinical Phenotype of Wild-Type, Heterozygous, and Homozygous JAK2V617F in Polycythemia Vera. Cancer. 2006; 106: 631-5.
Passamonti F and Rumi E. Clinical Relevance of JAK2 (V617F) Mutant Allele Burden. Haematologica. 2009; 94: 7-10.
Vannucchi AM, Pieri L and Guglielmelli P. JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. Therapeutic Advances in Hematology. 2011; 2: 21-32.
Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of Mutant JAK2-V617F to Wild-Type JAK2 Determines The MPD Phenotypes in Transgenic Mice. Blood. 2008; 111: 3931-40.
Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical Profile of Homozygous JAK2 V617F Mutation in Patients with Polycythemia Vera or Essential Thrombocythemia. Blood. 2007; 110: 840-6.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
